Letter to the Editor Regarding “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”

被引：0
|
作者：
Yafei Xie
Xiaowei Zhang
机构：
[1] Lanzhou University Second Hospital, Department of Cardiovascular Medicine
[2] Lanzhou University,Second Clinical Medical College
来源：
Cardiovascular Drugs and Therapy | 2022年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：571 / 572
页数：1
相关论文
共 50 条
  • [31] LX4211, a Dual Inhibitor of SGLT2 and SGLT1 Enhances the Effects of Sitagliptin in Patients With Type 2 Diabetes Mellitus (T2DM)
    Zambrowicz, Brian
    Ogbaa, Ike
    Powell, David
    Banks, Phillip
    Turnage, Anne
    Frazier, Kenny
    Boehm, Kristi A.
    Freiman, Joel
    Lapuerta, Pablo
    Sands, Arthur
    DIABETES, 2012, 61 : A248 - A249
  • [32] Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors
    Yakovleva, Tatiana
    Sokolov, Victor
    Chu, Lulu
    Tang, Weifeng
    Greasley, Peter J.
    Sjogren, Helena Peilot
    Johansson, Susanne
    Peskov, Kirill
    Helmlinger, Gabriel
    Boulton, David W.
    Penland, Robert C.
    DIABETES OBESITY & METABOLISM, 2019, 21 (12): : 2684 - 2693
  • [33] Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts
    Sanchez-Munoz, Enrique
    Requena-Ibanez, Juan Antonio
    Badimon, Juan Jose
    REVISTA ESPANOLA DE CARDIOLOGIA, 2024, 77 (07): : 510 - 514
  • [34] The Effect of SGLT2 Inhibition on Adenosine Excretion in Patients with Type 1 Diabetes
    Rajasekeran, Harindra
    Lytvyn, Yuliya
    Bozovic, Andrea
    Diamandis, Eleftherios
    Husain, Mansoor
    Advani, Andrew
    Perkins, Bruce A.
    Reich, Heather
    Kulasingam, Vathany
    Cherney, David
    DIABETES, 2016, 65 : A144 - A144
  • [35] LX4211, a Dual SGLT1/SGLT2 Inhibitor, Decreases Body Weight and Triglycerides in Patients With Type 2 Diabetes Mellitus and Elevated Baseline Values
    Zambrowicz, Brian
    Lapuerta, Pablo
    Ogbaa, Ike
    Banks, Phillip
    Frazier, Kenny
    Boehm, Kristi A.
    Kelly, Mike
    Sands, Arthur
    DIABETES, 2013, 62 : A62 - A62
  • [36] LX4211, a dual SGLT1/SGLT2 inhibitor, decreases body weight and triglycerides in patients with type 2 diabetes mellitus and elevated baseline values
    Zambrowicz, B.
    Lapuerta, P.
    Ogbaa, I.
    Banks, P.
    Frazier, K.
    Boehm, K. A.
    Kelly, M.
    Sands, A.
    DIABETOLOGIA, 2013, 56 : S399 - S399
  • [37] Effect of SGLT2 and dual SGLT1/2 Inhibition on the Development of Salt-induced Hypertension
    Levchenko, Vladislav
    Kravtsova, Olha
    Upadhyay, Gunjan
    Bohovyk, Ruslan
    Rieg, Timo
    PHYSIOLOGY, 2024, 39
  • [38] Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure
    Verbrugge F.H.
    Current Heart Failure Reports, 2017, 14 (4) : 275 - 283
  • [39] LX4211, a dual inhibitor of SGLT1/SGLT2, reduces postprandial glucose in patients with type 2 diabetes mellitus and moderate to severe renal impairment
    Lapuerta, P.
    Sands, A.
    Ogbaa, I.
    Strumph, P.
    Powell, D.
    Banks, P.
    Zambrowicz, B.
    DIABETOLOGIA, 2014, 57 : S324 - S324
  • [40] RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Moura, Filipe
    Berg, David
    Bellavia, Andrea
    Mosenzon, Ofri
    Dwyer, Jamie
    Scirica, Benjamin M.
    Wiviott, Stephen
    Bhatt, Deepak L.
    Raz, Itamar
    Feinberg, Mark William
    Morrow, David A.
    Sabatine, Marc Steven
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1808 - 1808
12345